Plymouth Pharmaceuticals, Inc. is a leading research and development company exploring safe, effective, oral therapies for inflammatory skin disorders.?Plymouth offers Rx and OTC products for psoriasis, eczema, acne and seborrhea dermatitis.
Kupiec Group is a consortium of scientific?professionals specializing?in pharmaceutical, genetic and forensic fields that provide knowledge-based?expert services to the legal and risk?management communities.
Kemmx Corporation is a start-up, biotechnology company pioneering the development and commercialization of targeted analgesics for chronic pain. Their topical analgesic formulations provide long lasting pain relief with minimal side effects.
PreDENT has developed a vaccine to help prevent gingivitis and periodontal disease in pets?that produces significant pain and possibly even fatal damage to an animal?s organs.
Cassion Biotech has developed a bio-superior drug delivery system, HEPylation ? System, which uses a patented composition designed to improve the performance of many powerful drug compounds in terms of safety, tolerability, efficacy, and quality.
Astellas is an international pharmaceutical company intensely focused on five key therapeutic areas: cardiology, dermatology, immunology, infectious disease, and urology.
DormaTarg, Inc is a biotechnology company researching and developing therapeutic drugs for cancer recurrence prevention.
Analytical testing laboratory that provides innovative methodologies for greater flexibility and higher throughput for data collection needs.
Biolytx Pharmaceuticals develops a novel antibiotic peptide for use in treatment of serious hospital-acquired infections, including those resistant to current antibiotics.
EpimedX, LLC is a biotechnology company that was founded in 2011 with the mission to develop Gene Regulation Therapy? ? a promising technology that is expected to provide a safe, cost-effective, and permanent treatment for sickle cell disease, beta-thalassemia, and malaria without dangerous or harmful side effects.
Tetherex is developing a treatment for inflammatory and thrombotic diseases such as Crohn’s disease. Preclinical studies have shown a positive impact in remission of the disease with evidence of potentially reversing the disease process.
Charlesson is an ocular pharmaceutical company that is developing therapeutics for various eye diseases, including wet and dry Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and Uveitis.
IPS Research Company provides phase 1-4 inpatient and outpatient clinical trials. IPS Research specializes in clinical drug trials dealing with psychiatric disorders, including Depression, Schizophrenia, Bipolar Depression, ADHD, GAD, PTSD, Dementia, Alzheimer?s Disease, Child Depression and a variety of Anxiety Disorders.
COARE Biotechnology is a research driven pharmaceutical company dedicated to developing novel therapeutic agents designed to treat solid tumor cancers.
Cytovance? Biologics adds significant value to biopharmaceutical development programs assisting companies to advance recombinant protein, antibody and cell-based therapeutic products rapidly and cost-effectively from the laboratory bench, through clinical development and to commercial launch in international markets.
Cosmetic Specialty Labs is skilled in developing high end, prestige skin care products, as well as custom formulated over the counter drugs.
Synereca Pharmaceuticals addresses the growing problem of bacterial resistance to current antibiotics by developing orally active drugs that restore or increase the effectiveness of existing antibiotics.
Heparinex is a biotechnology company focused on the development of novel recombinant synthesis of heparinoid compounds for various markets including anticoagulation, biomaterials, and cellular modulation applications.
Leviathan proposes a next-generation tool that will make it possible to distinguish and examine heterogeneous states among suspension cells in situ, with the potential for a significant increase in sensitivity, selectivity, resolution, and scalability over current technology.
Choncept?s scientific innovation is focused on development of new technology to produce chondroitin from fermentation of recombinant bacteria to replace the current chondroitin source of beef and other animal by-products.